[HTML][HTML] Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness

…, A Antoli, R Moreno-Gonzalez, S Yun, P Cerda… - International Journal of …, 2020 - Elsevier
Objectives To assess the characteristics and risk factors for mortality in patients with severe
coronavirus disease-2019 (COVID-19) treated with tocilizumab (TCZ), alone or in …

[HTML][HTML] PI3K (phosphatidylinositol 3-kinase) activation and endothelial cell proliferation in patients with hemorrhagic hereditary telangiectasia type 1

A Iriarte, A Figueras, P Cerdà, JM Mora, A Jucglà… - Cells, 2019 - mdpi.com
Hemorrhagic hereditary telangiectasia (HHT) type 2 patients have increased activation of
the phosphatidylinositol 3-kinase (PI3K) signaling pathway in telangiectasia. The main …

[HTML][HTML] Risk of recurrent venous thromboembolism after acute pulmonary embolism: Role of residual pulmonary obstruction and persistent right ventricular …

C Becattini, M Giustozzi, P Cerdà, LA Cimini… - Journal of Thrombosis …, 2019 - Elsevier
Cerdà performed statistical analysis, interpreted results, and drafted the manuscript. All …
Cerdà and G. Agnelli had full access to all data in the study, and take responsibility for the …

[HTML][HTML] Blood test dynamics in hospitalized COVID-19 patients: Potential utility of D-dimer for pulmonary embolism diagnosis

P Cerdà, J Ribas, A Iriarte, JM Mora-Luján, R Torres… - PloS one, 2020 - journals.plos.org
Background A higher incidence of thrombotic events, mainly pulmonary embolism (PE), has
been reported in hospitalized patients with COVID-19. The main objective was to assess …

[HTML][HTML] Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia: risk factors and endoscopic findings

…, MÁ Sánchez-Corral, A Berrozpe, P Cerdà… - Journal of Clinical …, 2019 - mdpi.com
Background: We aimed to describe risk factors for gastrointestinal (GI) bleeding and endoscopic
findings in patients with hereditary hemorrhagic telangiectasia (HHT). Methods: This is a …

Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: A meta-analysis.

P Cerdà, C Becattini, A Iriarte, JC Hernández… - European Journal of …, 2020 - Elsevier
… Author links open overlay panel Pau Cerdà a , Cecilia Becattini b , Adriana … Cerdà and A.
Riera-Mestre designed the study. P… Cerdà and A. Iriarte independently extracted study data. J. …

[HTML][HTML] Gender differences in hereditary hemorrhagic telangiectasia severity

…, A Iriarte, E Alba, MA Sánchez-Corral, P Cerdà… - Orphanet Journal of …, 2020 - Springer
Background Gender differences in organ involvement and clinical severity have been poorly
described in hereditary hemorrhagic telangiectasia (HHT). The aim of this study was to …

[HTML][HTML] Improving Hereditary Hemorrhagic Telangiectasia Molecular Diagnosis: A Referral Center Experience

C Aguilera, A Padró-Miquel, A Esteve-Garcia, P Cerdà… - Genes, 2023 - mdpi.com
Background: Hereditary hemorrhagic telangiectasia (HHT) is a rare vascular disease
inherited in an autosomal dominant manner. Disease-causing variants in endoglin (ENG) and …

[HTML][HTML] Long-term use of somatostatin analogs for chronic gastrointestinal bleeding in hereditary hemorrhagic telangiectasia

…, JM Mora-Luján, A Iriarte, P Cerdà… - Frontiers in …, 2023 - frontiersin.org
Background: Chronic bleeding due to gastrointestinal (GI) involvement in patients with
hemorrhagic hereditary telangiectasia (HHT) can provoke severe anemia with high red blood …

[HTML][HTML] Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

…, R López-Reyes, S Soler, A Ballaz, P Cerdà… - Orphanet Journal of …, 2019 - Springer
Background Limited data exist about the clinical presentation, ideal therapy and outcomes
of patients with hereditary hemorrhagic telangiectasia (HHT) who develop venous …